Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Lancet (London, England)
|
March 12, 1999
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
G P Aithal, C P Day, P J Kesteven, et al.
Clinical and Laboratory Haematology
|
January 1, 1985
Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders
P J Kesteven, J M Pullan, U H Glass, et al.
Clinical Otolaryngology and Allied Sciences
|
October 1, 1995
Do patients with epistaxis have drug-induced platelet dysfunction?
J R Livesey, M G Watson, P J Kelly, et al.
Thrombosis and Haemostasis
|
October 31, 1983
Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays
G F Savidge, P J Kesteven, S F Al-Hasani, et al.
The Journal of Cardiovascular Surgery
|
September 1, 1986
Protamine sulphate and heparin rebound following open-heart surgery
P J Kesteven, A Ahmed, C Aps, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
April 13, 2011
Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes
A Natarajan, S M Marshall, P J Kesteven, et al.
Intensive Care Medicine
|
January 1, 1990
Disseminated zygomycosis and systemic lupus erythematosus
C A Bloxham, S Carr, D W Ryan, et al.
British Heart Journal
|
October 1, 1995
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction
J P Mounsey, J S Skinner, T Hawkins, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Lancet (London, England)
|
March 12, 1999
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
G P Aithal, C P Day, P J Kesteven, et al.
Clinical and Laboratory Haematology
|
January 1, 1985
Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders
P J Kesteven, J M Pullan, U H Glass, et al.
Clinical Otolaryngology and Allied Sciences
|
October 1, 1995
Do patients with epistaxis have drug-induced platelet dysfunction?
J R Livesey, M G Watson, P J Kelly, et al.
Thrombosis and Haemostasis
|
October 31, 1983
Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays
G F Savidge, P J Kesteven, S F Al-Hasani, et al.
The Journal of Cardiovascular Surgery
|
September 1, 1986
Protamine sulphate and heparin rebound following open-heart surgery
P J Kesteven, A Ahmed, C Aps, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
April 13, 2011
Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes
A Natarajan, S M Marshall, P J Kesteven, et al.
Intensive Care Medicine
|
January 1, 1990
Disseminated zygomycosis and systemic lupus erythematosus
C A Bloxham, S Carr, D W Ryan, et al.
British Heart Journal
|
October 1, 1995
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction
J P Mounsey, J S Skinner, T Hawkins, et al.
Page
of 2